EUVIMEDEUVIMED entdecken
Crossref

Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit

Léo-Paul Bancel, Vincent Masso, Anne-Frederique Dessein, Sébastien Aubert, Emmanuelle Leteurtre, Lucie Coppin, Marie-Françoise Odou, Christine Do Cao, Catherine Cardot-Bauters, Pascal Pigny iD

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Léo-Paul Bancel und 9 weiteren Autor:innen. Beteiligte Einrichtung: CHU Lille, Laboratoire de Biochimie-Hormonologie, Métabolisme, Nutrition, Oncologie, Centre de Biologie Pathologie, F.59037 Lille Cedex, France. Hauptthemen laut MEDLINE: Pheochromocytoma, Paraganglioma, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Institut de Biochimie & Biologie Moléculaire.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Pheochromocytomas and paragangliomas (PPGLs) with SDHx pathogenic variants (PVs) are characterized by a higher intratissular succinate/fumarate ratio (RS/F) than non-SDHx–mutated ones. Also, an increase in serum succinate levels has been reported in patients with germline SDHB or SDHD PV.

Objective

To assess whether measurement of serum succinate, fumarate levels, and RS/F might aid identification of an SDHx germline PV/likely pathogenic variant (LPV) in patients with PPGL or in asymptomatic relatives; and to guide identification of a PV/LPV among the variants of unknown significance (VUS) identified in SDHx by next-generation sequencing.

Methods

This prospective monocentric study included 93 patients attending an endocrine oncogenetic unit for genetic testing. Succinate and fumarate were measured in serum by gas chromatography coupled to mass spectrometry. The RS/F was calculated to assess SDH enzymatic function. Diagnostic performance was assessed by receiver operating characteristic analysis.

Results

RS/F had a higher discriminant power than succinate alone to identify an SDHx PV/LPV in patients with PPGL. However, SDHD PVs/LPVs are frequently missed. Only RS/F differed between asymptomatic SDHB/SDHD PV/LPV carriers and SDHB/SDHD-linked patients with PPGL. Finally RS/F could be helpful to easily evaluate the functional impact of VUS in SDHx.

Conclusion

Measurement of serum RS/F in patients with PPGL and in asymptomatic relatives is a valuable initial workup tool to detect those carrying a germline PV/LPV in SDHx. Its discriminative power is equal or superior to those of succinate measured alone. SDHD PVs/LPVs are less frequently identified by these biochemical tools. Use of RS/F for SDHx VUS reclassification needs to be evaluated further.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PheochromocytomaParagangliomaAdrenal Gland NeoplasmsHumansSuccinic AcidFumaratesProspective StudiesSuccinate DehydrogenaseCarcinogenesisCell Transformation, NeoplasticGerm-Line Mutation

Stichwörter der Autor:innen

SDHenzyme deficiencyfumarateparagangliomapheochromocytomasuccinate

Substanzen

Succinic AcidFumaratesSuccinate Dehydrogenase

Autor:innen und Institutionen

  • CHU Lille, Laboratoire de Biochimie-Hormonologie, Métabolisme, Nutrition, Oncologie, Centre de Biologie Pathologie, F.59037 Lille Cedex, France.
  • CHU Lille, Service d'Anatomie Pathologique, Centre de Biologie Pathologie, F-59037 Lille Cedex, France.
  • University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to therapies, F-59000 Lille, France.
  • CHU Lille, Service d'Endocrinologie, Diabétologie, Métabolisme, Nutrition, Hôpital Claude Huriez, F-59037 Lille Cedex, France.

ORCID-Profile: Pascal Pigny

Förderung

  • Institut de Biochimie & Biologie Moléculaire

Zitieren

APA

Bancel, L. P., Masso, V., Dessein, A. F., Aubert, S., Leteurtre, E., Coppin, L., Odou, M. F., Do Cao, C., Cardot-Bauters, C., & Pigny, P. (2023). Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad109

Vancouver

Bancel LP, Masso V, Dessein AF, Aubert S, Leteurtre E, Coppin L, et al. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad109

BibTeX
@article{Bancel2023,
  author = {Bancel, Léo-Paul and Masso, Vincent and Dessein, Anne-Frederique and Aubert, Sébastien and Leteurtre, Emmanuelle and Coppin, Lucie and Odou, Marie-Françoise and Do Cao, Christine and Cardot-Bauters, Catherine and Pigny, Pascal},
  title = {Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad109}
}
Kostenlos starten →